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The sulbactam resistance rate in Acinetobacter baumannii has increased worldwide.
Previous reports have shown that the β-lactamase blaTEM−1 confers resistance to
sulbactam in A. baumannii. The purpose of this study was to examine whether
other β-lactamases, including the Acinetobacter-derived cephalosporinase (ADC),
OXA-23, OXA-24/72, and OXA-58 families, also contribute to sulbactam resistance
in A. baumannii. The correlation between these β-lactamases and the sulbactam
minimal inhibitory concentration (MIC) was determined using A. baumannii clinical
isolates from diverse clonality, which were collected in a nationwide surveillance program
from 2002 to 2010 in Taiwan. A possible association between the genetic structure
of ISAba1-blaADC−30 and sulbactam resistance was observed because this genetic
structure was detected in 97% of sulbactam-resistant strains compared with 10%
of sulbactam-susceptible strains. Transformation of ISAba1-blaADC−30 into susceptible
strains increased the sulbactam MIC from 2 to 32µg/ml, which required blaADC−30
overexpression using an upstream promoter in ISAba1. Flow cytometry showed that
ADC-30 production increased in response to sulbactam, ticarcillin, and ceftazidime
treatment. This effect was regulated at the RNA level but not by an increase in
the blaADC−30 gene copy number as indicated by quantitative PCR. Purified ADC-30
decreased the inhibitory zone created by sulbactam or ceftazidime, similarly to TEM-1. In
conclusion, ADC-30 overexpression conferred resistance to sulbactam in diverse clinical
A. baumannii isolates.
Keywords: sulbactam, mechanisms of resistance, Acinetobacter baumannii, transformation,
Acinetobacter-derived cephalosporinase (ADC)
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Introduction
Acinetobacter baumannii causes various nosocomial infections,
and the prevalence of multidrug-resistant (MDR) A. bauman-
nii has been increasing in different countries. This bacterium
has intrinsic resistance to multiple drugs and can gain resis-
tance mechanisms from other species (Peleg et al., 2008).
The SENTRY program documented non-susceptibility to car-
bapenems, the last resort of drugs for the treatment of MDR
A. baumannii, increased from 34.5% in 2006 to 59.8% in
2009 worldwide (Gales et al., 2011). In Taiwan, the rate of
multidrug resistance in Acinetobacter spp. also increased from
1.3% in 2002 to 41.0% in 2010 (Kuo et al., 2012). In severely
ill patients, infections with MDR isolates have been associ-
ated with high mortality due to the absence of appropriate
or effective treatment options (Peleg et al., 2008). Combina-
tion therapies or new drugs such as antimicrobial peptides or
silver nanoparticles have been proposed as novel modalities
to treat MDR A. baumannii (Peleg et al., 2008; Tiwari et al.,
2014)
Sulbactam is a β-lactamase inhibitor that is typically combined
with penicillins because sulbactam lacks antimicrobial activity
against most bacterial species (Adnan et al., 2013). However,
sulbactam has demonstrated bacteriostatic or bactericidal effects
against A. baumannii (Corbella et al., 1998). Combination treat-
ment with sulbactam and carbapenems has shown promising
in vivo and in vitro synergistic effects against MDR A. baumannii
(Wolff et al., 1999; Ko et al., 2004; Song et al., 2007), and clinical
success has been reported (Karageorgopoulos and Falagas, 2008).
The addition of sulbactam to other antibiotics has been proposed
in the treatment of MDR A. baumannii; however, the resistance
rate to ampicillin/sulbactam in Acinetobacter spp. has increased
to approximately 60% in certain area (Kuo et al., 2012).
Until recently, the mechanism underlying sulbactam resis-
tance in A. baumannii was less commonly studied. In 2013, Kri-
zova and colleagues demonstrated that the β-lactamase TEM-1
contributes to sulbactam resistance (Krizova et al., 2013), which
led us to examine whether other selected β-lactamases found in
A. baumannii, including theAcinetobacter-derived cephalospori-
nase (ADC), OXA-23, OXA-24/72, and OXA-58 families, also
contribute to sulbactam resistance. Using clinical isolates col-
lected from a Taiwanese surveillance program, we aimed to iden-
tify the β-lactamases associated with sulbactam resistance and
to test the role of these β-lactamases in sulbactam resistance in
A. baumannii.
Materials and Methods
Association of Selected β-Lactamases with
Sulbactam Resistance in A. baumannii
A. baumannii clinical isolates were randomly selected from
the Taiwan Surveillance of Antimicrobial Resistance (TSAR)
program, which contains 1640 Acinetobacter isolates collected
from 2002 to 2010 (Kuo et al., 2012). A. baumannii was identi-
fied at the species level using multiplex PCR targeting the spe-
cific 16-23S rDNA intergenic spacer region (Chen et al., 2007).
Pulsed-field gel electrophoresis was performed to determine
clonality as previously described (Kuo et al., 2013). Isolates
with similarity of >80% was designated as a single clone. The
sulbactam-resistant and sulbactam-susceptible isolates were ran-
domly selected and subjected to PCR testing for the presence
of genes encoding ADC, OXA-23, OXA-24/72, and OXA-58 β-
lactamases (Table S1). The PCR program (Krizova et al., 2013;
Kuo et al., 2013) for genes encoding OXA was as followed:
94◦C for 1min, and 30 cycles of 25 s at 94◦C, 40 s at 52◦C
and 50 s at 72◦C; for PCR of blaADC, 30 cycles of 60 s at 94
◦C,
60 s at 58◦C, and 120 s at 72◦C. GoTaq Flexi DNA polymerase
(Promega, Madison, WI) was used for PCR assays performed
in the GeneAmp PCR System 2700 (Applied Biosystems, Foster
City, CA). Amplified DNA product was resolved by electrophore-
sis in agarose 2% w/v gels, stained with ethidium bromide, and
purified according to the manufacturer’s instruction (Geneaid
Biotech Ltd, Taipei, Taiwan).
Transformation of Plasmids Carrying Different
β-Lactamase Genes
Representative β-lactamase genes and their associated pro-
moters, including blaTEM−1, blaADC and blaOXA−23 with
their upstream insertion sequence ISAba1 (ISAba1-blaADC and
ISAba1-blaOXA−23, respectively), blaOXA−24/72, and blaOXA−58
with its upstream ISAba3 that was truncated with IS1008
(IS1008–1ISAba3-blaOXA−58) (Chen et al., 2010), were PCR-
amplified using the forward and reverse primers shown in
Table S1. The PCR products were amplified with a proof-
reading DNA polymerase (Phusion High-Fidelity DNA Poly-
merase, Finnzymes, Espoo, Finland), cloned into the pCRII-
TOPO vector (Invitrogen, Carlsbad, CA, USA) and subjected
to sequencing (Mission Biotech, Taipei, Taiwan). The digested
fragments were cloned into the XbaI and XhoI sites of the
Escherichia coli-A. baumannii shuttle vector pYMAb2 (Kuo
et al., 2013), which contains a kanamycin-resistant determi-
nant. The fragment was cloned in-frame with a polyhistidine
(His) tag, causing the resulting protein to be His-tagged. The
recombinant plasmid and a control plasmid (pYMAb2 with-
out β-lactamase genes) were transformed into the kanamycin-
susceptible A. baumannii strain ATCC15151. ATCC15151
already contained blaOXA−51; therefore, blaOXA−51was not
included in the experiment. Electroporation was performed with
a gene pulser electroporator (Bio-Rad, Hercules, CA, USA) and
2-mm electrode gap cuvettes (Kuo et al., 2013). Transformants
were selected based on kanamycin resistance, and sequencing
was performed to confirm the presence of each β-lactamase
gene.
Antimicrobial Susceptibility
Minimal inhibitory concentrations (MICs) of sulbactam, cef-
tazidime, ampicillin, imipenem, meropenem, and ticarcillin were
determined by the agar dilution method according to the guide-
lines provided by the Clinical and Laboratory Standards Insti-
tute (CLSI) (Clinical and Laboratory Standards Institute, 2012).
Sulbactam susceptibility parameters were adopted from the pre-
vious CLSI guidelines in which sulbactam MICs of less than 4
or more than 16µg/ml were defined as susceptible or resistant,
respectively.
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Immunofluorescent Staining and Enumeration by
Flow Cytometry for Protein Expression
Immunofluorescent staining was performed as previously
described with several modifications (Moe et al., 1999). Specif-
ically, bacterial cultures were diluted in phosphate buffered
saline (PBS) to ∼108 CFU/mL, and 0.5-ml samples were trans-
ferred into 1.5-ml Eppendorf microtubes. The samples were
centrifuged at 5000 × g for 5min, washed with 0.1% NaN3
PBS, and centrifuged for 5min. The resulting bacterial pellet
was resuspended in fixative (4% paraformaldehyde in PBS) for
20min. The fixed samples were washed twice with quench-
ing solution (100mM NaCl, 50mM Tris-HCl, pH 8.0) and
resuspended in permeable buffer (1% Triton X-100, 0.1% NaN3
in PBS) for 5min. After centrifugation, the samples were resus-
pended in 500µL blocking buffer (1% BSA and 0.1% NaN3
in PBS).
To identify His-tagged ADC-30 expressed by ATCC15151
(pYMAb2::ISAba1-blaADC−30), each 100-µL sample was incu-
bated with 2µL of mouse anti-His-6-tag antibody (Sigma-
Aldrich, St. Louis, MO, USA) at 4◦C for 2 h. After washing by
blocking buffer, the samples were stained for 1 h at 4◦C with
5µL of phycoerythrin (PE)-conjugated anti-mouse IgG antibody
(Sigma-Aldrich). The stained samples were spun at 5000 × g
for 5min, and the cell pellet was resuspended in 500µL of 1%
paraformaldehyde buffer and stored at 4◦C overnight. Cytom-
etry samples were resuspended in PBS and analyzed in a flow
FIGURE 1 | Molecular characteristics of randomly selected
Acinetobacter baumannii from the Taiwan Surveillance of
Antimicrobial Resistance (TSAR) program, 2002–2010. The results
of pulsed-field gel electrophoresis are shown, followed by the minimal
inhibitory concentrations (MICs), and the presence of
ISAba1-blaADC−30, blaTEM−1, ISAba1-blaOXA−23−lke, blaOXA−24−like,
and blaOXA−58−like in the (A) sulbactam-resistant strains and (B)
sulbactam-susceptible strains.
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cytometer system with wavelength of 575 nm (FACScanto II, BD
Biosciences, San Jose, CA, USA).
Quantitative PCR (qPCR) to Determine the
blaADC−30 Gene Copy Number after Challenging
with Different Antimicrobials
ATCC15151 (pYMAb2::ISAba1-blaADC−30) strains at mid-log
phase were incubated in Luria-Bertani (LB) broth with differ-
ent antimicrobial agents (25% of MIC) for 6 h. The blaADC−30
copy number in these bacteria was estimated by qPCR using
primers targeting blaADC−30, and the housekeeping gene, recA,
was used as an internal control. Each qPCR reaction contained
a total volume of 10µL with 2 ng of genomic DNA as template,
100 nmol/L of each primer, and 1 × SYBR Green R© PCR Mas-
ter Mix (Applied Biosystems, Carlsbad, CA, USA) with ROX™
(Kapa Biosystems, Woburn, MA, USA). The relative blaADC−30
copy number in the bacteria treated with different antimicro-
bial agents was normalized to the number found in the bac-
teria treated with LB broth without antimicrobial agents. The
qPCR conditions included 2min at 50◦C (UNG activation),
10min at 95◦C, followed by 45 cycles of 15 s at 95◦C and 1min
at 60◦C. At the end, a dissociation stage was added: 15 s at
95◦C, 15 s at 60◦C, and 15 s at 95◦C. All experiments were con-
ducted using the ABI 7500 Fast Real-time PCR system (Applied
Biosystems, Inc., Carlsbad, CA, USA) and were performed in
triplicate.
Quantitative Reverse Transcription PCR
(qRT-PCR) to Assess mRNA Expression after
Challenging with Different Antimicrobials
After incubation with different antimicrobial agents, the ADC-30
mRNA levels in ATCC15151 (pYMAb2::ISAba1-blaADC−30) were
compared using qRT-PCR (Chen et al., 2010). Briefly, around
2µg of RNA was extracted with RNAprotect Bacteria Reagent
and an RNeasy mini-kit (Qiagen, Valencia, CA, USA). Resid-
ual genomic DNA was removed using RNase-free DNase. The
RNA was reverse transcribed into single-stranded cDNA with
random hexamers and Moloney Murine Leukemia Virus reverse
transcriptase (Epicenter, Madison, WI, USA). The cDNAs were
subsequently quantified by real-time PCR amplification with
conditions mentioned above. Expression level results were stan-
dardized to the transcription levels of rpoB gene for each strain,
but relatively to the culture in LB (2 delta–delta Ct method). Neg-
ative controls without reverse transcription were performed to
detect DNA contamination in the purified RNA.
ADC-30 Purification
His-tagged ADC-30 (in which the stop codon was deleted, and
the proteins were fused with 6 His amino acids) expressed
by ATCC15151 (pYMAb2::ISAba1-blaADC−30) was purified with
Ni-NTA Superflow column (Qiagen). Briefly, the bacteria equal
to ∼107 CFU/ml were centrifuged, resuspended in lysis buffer
and sonicated. The lysate was diluted in binding buffer (25mM
Tris, 150mM NaCl, 10mM imidazole, pH 7.5) and loaded onto
the column. The column was washed with five column volumes
of wash buffer, and the protein was eluted with five column
volumes of elution buffer (25mM Tris, 150mM NaCl, 300mM
imidazole). The protein solution was then dialyzed and concen-
trated by ultrafiltration on a 10 KDa-cutoff Amicon membrane
(Millipore). The purity was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blotting as greater than 95%.
SDS-PAGE and Western Blotting to Detect
Purified β-Lactamases
For SDS-PAGE and Western blotting (Blair et al., 2009), the
purified protein was first separated by SDS-PAGE on 12% acry-
lamide gel using Mini-PROTEAN system (Bio-Rad) and trans-
ferred to a nitrocellulose membrane (PerkinElmer, Boston, MA,
USA) in transfer buffer (25mM Tris-HCl, 190mM glycine, 20%
methanol, 0.1% SDS, pH 8.3) at 350mA for 1 h. The membranes
were blocked with 10% non-fat driedmilk in Tris-bufferred saline
with 0.5% Tween-20. After hybridization with anti-His antibod-
ies (Sigma-Aldrich) and peroxidase-conjugated goat anti-mouse
secondary antibodies (Millipore, Temecula, CA, USA), the band
was visualized with an ECL Western blot kit (PerkinElmer,
Boston, MA, USA).
Bioassays to Confirm the Activity of Purified
ADC-30 against Ceftazidime and Sulbactam
The first bioassay involved themixture of 10µL of purified ADC-
30 or extracts of sulbactam- resistant or -susceptible strains with
TABLE 1 | Minimal inhibitory concentrations (µg/ml) of Acinetobacter baumannii reference strain and different transformants.
Strains Sulbactam Ceftazidime Ampicillin Imipenem Meropenem Ticarcillin
ATCC15151 2 8 64 0.25 0.5 16
ATCC15151 (pYMAb2) 2 8 64 0.25 0.5 16
ATCC15151 (pYMAb2::ISAba1-blaADC−30 ) 32 512 >1024 2 4 128
ATCC15151 (pYMAb2::blaADC−30 1 P1 [deletion of -35 promoter]) 4 32 256 0.25 0.25 32
ATCC15151 (pYMAb2::blaADC−30 1P2 [deletion of -10 and -35 promoter]) 4 32 64 0.5 0.25 16
ATCC15151 (pYMAb2::ISAba1-blaOXA−23 ) 16 8 >1024 16 16 >1024
ATCC15151 (pYMAb2::blaOXA−24/72 ) 4 8 1024 16 64 512
ATCC15151 (pYMAb2::IS1008–1ISAba3-blaOXA−58 ) 8 4 >1024 16 8 >1024
ATCC15151 (pYMAb2:: blaTEM−1) 16 8 >1024 0.25 0.25 >1024
ATCC15151 (pYMAb2:: blaTEM−1 1P [deletion of promoter]) 4 8 64 0.25 0.25 32
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FIGURE 2 | ADC-30 production in response to treatment with
sulbactam and other substrates. (A) Flow cytometry showed that
the ADC-30 protein expression level increased in response to its
substrates (ceftazidime, sulbactam, and ticarcillin) compared with the
level observed in bacteria cultured in Luria-Bertani (LB) broth without
antimicrobial agents. The tests were performed in triplicate; however,
only one of the representative experiments is shown. (B) Quantified
values of experiments performed in triplicate are shown in the bar
graph. LB broth supplemented with kanamycin was used as a positive
control because pYMAb2 also carries a kanamycin resistance
determinant. CAZ, ceftazidime; CIP, ciprofloxacin; IPM, imipenem; KAN,
kanamycin; SUL, sulbactam.
10µL of ceftazidime for 30min at 37◦C. Each 20-µL mixture
was loaded onto a blank disk (Becton Dickinson, Sparks, MD,
USA) that was placed in an agar plate containing a lawn of
ceftazidime-susceptible A. baumannii ATCC 15151. Inhibitory
zones were measured after incubating the plates overnight at
37◦C.
The second bioassay conducted was similar to the modified
Hodge test for carbapenemase detection. A 0.5 McFarland
standard suspension of the sulbactam-susceptible A. bauman-
nii ATCC 15151 strain was diluted to 1:10 and inoculated
on an Mueller-Hinton agar plate for routine disk diffusion
test. The 30-µg sulbactam disk was placed in the center of
the plate, and the purified ADC-30, TEM-1, or PBS samples
were drawn in a straight line out from the edge of the disk.
The phenotype was evaluated after an overnight incubation at
37◦C.
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Results and Discussion
Detection of Selected β-Lactamases in Clinical A.
baumannii Isolates using a Nationwide
Surveillance System
Of the 30 sulbactam-resistant isolates tested, 14 (47%) were
positive for blaTEM−1, and 29 (97%) possessed blaADC with
ISAba1 upstream (ISAba1-blaADC). The PFGE shown in Figure 1
depicts the strain diversity. Based on clonality, 19 isolates
belonging to different clones and carrying ISAba1-blaADC were
sent for sequencing. The blaADC sequences of all 19 strains
were consistent with the blaADC−30 sequence. ISAba1-blaOXA−23,
blaOXA−24/72 and IS1008–1ISAba3-blaOXA−58 were present
in16, 6, and 0 isolates, respectively. In 10 sulbactam-susceptible
isolates, one possessed ISAba1-blaADC−30. None of the isolates
possessed blaTEM−1. Therefore, in addition to TEM-1(Krizova
et al., 2013), ISAba1-blaADC−30 may play a role in providing
A. baumannii with sulbactam resistance.
The presence of one resistant strain without ISAba1-blaADC
nor blaTEM−1 indicates that another mechanism may be
involved in sulbactam resistance. Various combinations of resis-
tance mechanisms, including β-lactamase overexpression, the
up-regulation of the eﬄux pump and the inactivation or down-
regulation of porin, are often required for the development of
FIGURE 3 | BlaADC−30 mRNA expression level and gene copy
number in response to treatment with sulbactam and other
antimicrobial agents. (A) The blaADC−30 mRNA expression level
increased after treatment with sulbactam and ceftazidime. ATCC15151
(pYMAb2::ISAba1-blaADC−30 ) treated with ciprofloxacin or without
antimicrobial agents were used as negative controls. (B) The blaADC−30
gene copy number did not differ, regardless of the antimicrobial agents
added. The mRNA expression level increased in response to kanamycin
because of the increased number of plasmids (pYMAb2) carrying the
kanamycin-resistant gene. The test was performed in triplicate. CAZ,
ceftazidime; CIP, ciprofloxacin; KAN, kanamycin; LB, Luria-Bertani broth;
SUL, sulbactam.
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β-lactam resistance in Pseudomonas aeruginosa and A. bauman-
nii (Quale et al., 2006; Peleg et al., 2008; Tiwari et al., 2012;
Tiwari and Moganty, 2014), which may explain the presence of
ISAba1-blaADC−30 in one susceptible strain. However, the high
rate of ISAba1-blaADC−30 in resistant strains and its low rate in
susceptible strains (97% vs. 10%, Chi-square test p < 0.001) indi-
cate the importance of ISAba1-blaADC−30 for the development of
sulbactam resistance.
Contribution of ADC-30 and ISAba1 to Sulbactam
Resistance
To further confirm the association observed in the epidemio-
logical survey, ISAba1-blaADC−30, blaTEM−1,ISAba1-blaOXA−23,
blaOXA−24/72 (and its promoter), and IS1008–1ISAba3-
blaOXA−58 were cloned and transformed into a sulbactam-
susceptible reference strain, respectively. Shuttle vectors were
also transformed, and changes in the MICs were measured
(Table 1).
ATCC15151 (pYMAb2::ISAba1-blaADC−30) exhibited
the highest increases of sulbactam MIC (16-fold). Other
β-lactamases, including OXA-23, OXA-72, and OXA-58, con-
tributed to the increase in the sulbactam MICs, although at
FIGURE 4 | Activity of ADC-30 against ceftazidime and sulbactam. (A)
ADC-30 remained active against ceftazidime in Acinetobacter baumannii after
purification. Disks containing ceftazidime and different samples were placed in
an agar plate containing a lawn of ceftazidime-susceptible A. baumannii ATCC
15151. Crude extract of the ATCC15151 (pYMAb2::ISAba1-blaADC−30 ) strain
and purified ADC-30 (denoted as S1 and S2 in the lower filed) promoted the
growth of the A. baumannii ATCC 15151 strain against disks loaded with
ceftazidime. Controls included N1 (phosphate buffered saline) and N2 [crude
extract of ATCC15151 (pYMAb2)], with which the ceftazidime created an
inhibitory zone. (B) The bioassay resembling modified the Hodge test showed
that purified ADC-30 and TEM-1 both promoted A. baumannii ATCC 15151
growth against sulbactam. PBS, phosphate buffered saline.
lower levels. ISAba1-blaADC−30 was used in the study due to
the high level of sulbactam resistance and high prevalence of
ISAba1-blaADC−30, which were comparable to the sulbactam
resistance levels and prevalence of blaTEM−1.
The regulatorymechanism for ADC expression inAcinetobac-
ter spp. may be different from themechanism inmany Enterobac-
teriaceae because Acinetobacter spp. lack the AmpR gene (Jacoby,
2009). The presence of ISAba1 upstream of blaAmpC is essential
for ceftazidime resistance due to the AmpC overexpression (Her-
itier et al., 2006). To confirm the role of the promoter located
within ISAba1 in mediating sulbactam resistance, plasmids har-
boring blaADC−30 without upstream -35 (within ISAba1) or -
35/-10 promoters were transformed into ATCC15151. The MICs
increased by only 2-fold compared with the control (Table 1).
Therefore, as previous studies have indicated (Heritier et al.,
2006), these promoters in the ISAba1 are required for ADC-
mediated sulbactam resistance. Similarly, deletion of the pro-
moter upstream of blaTEM−1 decreased the sulbactam MIC.
ADC-30 Production in Response to Treatment
with Sulbactam and Other Substrates
The production of β-lactamase usually increases in response to
its substrates; therefore, we asked whether the addition of sulbac-
tam increases ADC-30 production. Flow cytometry (Figure 2)
showed that ADC-30 protein expression increased significantly
after the addition of sulbactam or ceftazidime compared with
the control. ADC-30 production was also induced by ticarcillin
but not by ciprofloxacin or imipenem. The results indicate that
the co-selection of sulbactam resistance by other antimicrobial
agents occurs.
The qRT-PCR results (Figure 3) showed that ADC-30 mRNA
expression increased in response to its substrates (ceftazidime
and sulbactam) but not in response to other antimicrobial agents
(ciprofloxacin). Carbapenemase expression has been related to
the high blaOXA−58 plasmid copy number (Bertini et al., 2007;
Chen et al., 2008). Therefore, we asked whether the increased
ADC-30 protein and mRNA expression levels in the presence
of sulbactam or ceftazidime are attributed to an increase in the
blaADC−30 copy number. The qPCR results (Figure 3) showed
no differences in the blaADC−30 copy numbers of cells treated
with sulbactam or ceftazidime compared with the negative con-
trols. In contrast, the gene copy number increased in response to
kanamycin. The results indicate that the increase in ADC-30 was
regulated at the RNA level.
How the addition of sulbactam increased ADC-30 protein
and mRNA expression level in A. baumannii is unknown. The
induction of AmpC by β-lactams has been commonly described
in P. aeruginosa and many Enterobacteriaceae (Jacoby, 2009).
After the treatment of β-lactams, altered peptidoglycan synthesis
leads to increased expression of AmpC through AmpG–AmpR–
AmpC pathway (Zeng and Lin, 2013). Clavulanate, another β-
lactamase inhibitor with structure similar to β-lactams, also
induces the expression of AmpC in many Enterobacteriaceae
(Drawz and Bonomo, 2010). Although sulbactam may interfere
the wall synthesis by interacting with penicillin-binding protein
1 and 3 (Penwell et al., 2015), lack of AmpR in A. baumannii
indicated other mechanisms, rather than AmpG–AmpR–AmpC
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pathway, are responsible. The two-component system has been
proposed to be involved in the induction of AmpC and other
chromosomally encoded β-lactamases (Jacoby, 2009; Zeng and
Lin, 2013). However, the mechanism regarding the induction of
ADC in response to sulbactam in A. baumannii requires further
investigation.
Contribution of Purified ADC-30 to Sulbactam
Resistance
ADC-30 was purified (Figure S1), and the addition of puri-
fied ADC-30 to the disk decreased the inhibitory zone caused
by ceftazidime (Figure 4A), confirming the activity of the puri-
fied protein. The bioassay resembling the modified Hodge test
showed that purified ADC-30 promoted the inward growth of
sulbactam-susceptible A. baumannii similarly to purified TEM-
1 (Figure 4B). Therefore, ADC-30 may directly interact with
sulbactam and confer sulbactam resistance.
In conclusion, blaADC−30 overexpression contributes to sul-
bactam resistance in A. baumannii, which is prevalent in clinical
isolates of different clones in Taiwan over a long period of time.
The resistance mechanisms are induced at the mRNA and pro-
tein levels by other antimicrobial agents in addition to sulbac-
tam, supporting the cautious use of these antibiotics to avoid the
selection of sulbactam-resistant A. baumannii isolates.
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